Skip to main content

Table 4 Standardized incidence ratios (SIRs) for cancer classified according to the GLOBOCAN categories

From: Characterization and risk estimate of cancer in patients with primary Sjögren syndrome

Cancer categories Total (n = 1239)a Women (n = 1145) Men (n = 94)
Obs‡ Exp SIR LCI UCI Obs Exp SIR LCI UCI Obs Exp SIR LCI UCI
All cancers† 121 63.77 1.9 1.59 2.27 105 56.77 1.85 1.53 2.24 16 7 2.29 1.4 3.73
Solid cancers§ 60 53.1 1.13 0.88 1.46 55 47.42 1.16 0.89 1.51 5 5.68 0.88 0.37 2.12
 Thyroid 4 0.79 5.05 1.89 13.45 4 0.77 5.17 1.94 13.79 0 0.02 0
 Lip, oral cavity 4 0.99 4.05 1.52 10.8 4 0.83 4.81 1.81 12.83 0 0.16 0
 Stomach 5 2.24 2.23 0.93 5.36 5 1.98 2.53 1.05 6.07 0 0.26 0
 Kidney 3 1.67 1.8 0.58 5.57 2 1.44 1.39 0.35 5.55 1 0.23 4.39 0.62 31.14
 Brain, nervous system 2 1.17 1.72 0.43 6.86 2 1.07 1.87 0.47 7.48 0 0.1 0
 Gallbladder 1 0.77 1.3 0.18 9.2 1 0.72 1.39 0.2 9.83 0 0.05 0
 Lung 6 4.66 1.29 0.58 2.87 4 3.43 1.17 0.44 3.11 2 1.23 1.63 0.41 6.5
 Prostate 2 1.66 1.2 0.3 4.81       2 1.66 1.2 0.3 4.81
 Melanoma of skin 2 1.73 1.16 0.29 4.62 2 1.63 1.23 0.31 4.92 0 0.1 0
 Bladder 2 2.1 0.95 0.24 3.8 2 1.48 1.35 0.34 5.42 0 0.63 0
 Colorectal 9 10.08 0.89 0.46 1.72 9 9.02 1 0.52 1.92 0 1.06 0
 Breast 14 15.68 0.89 0.53 1.51 14 15.68 0.89 0.53 1.51      
 Pancreas 2 2.29 0.87 0.22 3.5 2 2.1 0.95 0.24 3.8 0 0.18 0
 Cervix uteri 1 1.39 0.72 0.1 5.1 1 1.39 0.72 0.1 5.1      
 Corpus uteri 2 3.72 0.54 0.13 2.15 2 3.72 0.54 0.13 2.15      
 Ovary 1 2.16 0.46 0.07 3.28 1 2.16 0.46 0.07 3.28      
Hematologicalb 50 4.54 11.02 8.35 14.54 42 4.14 10.14 7.49 13.72 8 0.39 20.34 10.17 40.67
 Leukemia 3 1.49 2.02 0.65 6.26 2 1.34 1.49 0.37 5.95 1 0.14 7.02 0.99 49.8
 MM/ID and lymphoma 47 3.05 15.41 11.58 20.51 40 2.80 14.29 10.48 19.48 7 0.25 27.91 13.31 58.54
  Hodgkin lymphoma 4 0.21 19.41 7.29 51.72 3 0.19 15.87 5.12 49.21 1 0.02 58.64 8.26 416.27
  MM/ID 31 0.86 36.17 25.44 51.43 28 0.79 35.59 24.58 51.55 3 0.07 42.58 13.73 132.03
  Non-Hodgkin lymphoma 12 1.99 6.04 3.43 10.64 9 1.82 4.94 2.57 9.49 3 0.16 18.37 5.93 56.96
  1. Obs observed, Exp expected, SIR standardized incidence ratios, LCL lower confidence limit, UCL upper confidence limit, MM/ID myeloma multiple and malignant immunoproliferative diseases
  2. aExcluding patients diagnosed with cancer before fulfillment of primary SjS criteria (n = 55) and patients with an age at SjS diagnosis <15 years (n = 6) (the age category “0–14” was excluded when SIR were computed). From 6 patients with an age at SjS diagnosis <15 years, one was diagnosed with cancer
  3. bExcluding 7 patients with hematological neoplasia not included in the GLOBOCAN categories (1 refractory cytopenia with multilineage dysplasia, 1 refractory anemia with unilineage dysplasia, 1 refractory anemia with excess blasts, 1 myelodisplastic syndrome unclassifiable, 1 mastocytosis, 1 essential thrombocythemia, and 1 angioimmunoblastic T-cell lymphoma) (see Additional file 1: Table S5) and 4 patients who developed first a solid cancer and subsequently a hematological cancer
  4. †Excluding patients with non-melanoma skin cancer (n = 4, not included in the GLOBOCAN classification) and a non-classifiable skin cancer (n = 1, uncertain whether was a melanoma or non-melanoma cancer)
  5. §Excluding 4 patients with neoplasia not included in the GLOBOCAN categories (2 endocrine, 2 ocular)